Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Lancet Oncol. 2023 Jul;24(7):811–822. doi: 10.1016/S1470-2045(23)00246-2

Table 3.

Efficacy of BCMA CAR T cells combined with a GSI

Patients (n=18) BCMA Naïve (n=11) BMCA Exposed (n=7)
Best overall response 89% (16) 100% (11) 71% (5)
  Stringent CR 8 (44%) 8 (73%) (0)
  Complete response 11% (2) 18% (2) 0% (0)
  Very good partial response 4 (22%) 1 (9%) 3 (43%)
  Partial response 11% (2) 0% (0) 29% (2)
  Stable disease 11% (2) 0% (0) 29% (2)
  Progressive disease 0% (0) 0% (0) 0% (0)
Survival (95% CI)
  Progression free survival 11 months (5.4 – not reached) 28.8 months (19.2-not reached)_ 2.6 months (1.1-not reached)
  Overall survival 42 months (13.2 – not reached) 42 months (42-not reached) 6.8 months (1.1-not reached)